secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0001213900-25-034218
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt subsidiary Pearsanta receives IRB approval to begin clinical studies for endometriosis blood test
--------------------------------------------------------------------------------

- Pearsanta received IRB approval to start clinical studies for a blood-based diagnostic test for endometriosis using mitochondrial DNA analysis.
- Test uses Mitomic technology to detect disruptions in mitochondrial DNA from a blood sample; aims to replace invasive laparoscopic diagnosis.
- Clinical validation targets ~100 samples from OB-GYN sites; commercial launch as an LDT targeted for end of June 2025.
- Next test in pipeline is for prostate cancer; Richmond CLIA/CAP lab to process samples.
- Collaborating with Evofem to recruit OB-GYN sites for the study; highlights synergies between subsidiaries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025034218/0001213900-25-034218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025034218/ea0239164-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-034218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer